No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S N/A · No P/S — trailing revenue unavailable or non-positive.
Annualized revenue (TTM) · by quarter, last 15
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
The latest delayed quote for MIRA Pharmaceuticals, Inc. (MIRA) stock was $0.73 as of Oct 6, 2026, 12:20 PM EDT, down 0.71% from the previous close.
Longer view (total return, dividends reinvested): past 12 months -45.4% · 3-year avg -46.1%/yr
MIRA Pharmaceuticals, Inc. operates as a biopharmaceutical enterprise currently in the clinical development phase.
Drug Manufacturers - General · Miami, FL
Next Earnings Date
Dec 2, 2026
57 days away
EPS Estimate
-0.03
Revenue Est.
N/A
Last Quarter Results
EPS
$-0.03
vs Estimate
N/A
Revenue
$0.00
vs Estimate
N/A
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1MIRA | $30.69M | $0.73 | -0.71% | -45.36% | N/A | N/A | N/A |
| 2CRVO | $30.28M | $3.27 | -1.21% | -61.36% | -38.25% | -53.96% | vs MIRA |
| 3MDXH | $30.17M | $0.59 | -1.61% | -87.47% | N/A | N/A | vs MIRA |
| 4NSYS | $31.44M | $11.25 | +1.81% | +22.66% | -1.64% | +11.22% | vs MIRA |
| 5GRDX | $29.88M | $4.19 | +9.40% | -11.92% | -83.84% | N/A | vs MIRA |
| 6CNTX | $29.84M | $0.32 | -3.48% | -69.24% | N/A | N/A | vs MIRA |
forward FY estimate
N/A
Consensus Rating
Based on 1 analyst
Average Price Target
$3.50
+379.3% upside
Low
$3.50
Current
$0.73
High
$3.50
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.03 | $-0.03 | $-0.03 | 1 |
| Quarter ending Dec 2026 | $-0.03 | $-0.03 | $-0.03 | 1 |
| Quarter ending Mar 2027 | $-0.04 | $-0.04 | $-0.04 | 1 |
| Quarter ending Jun 2027 | $-0.04 | $-0.04 | $-0.04 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-0.12 | $-0.12 | $-0.12 | 1 |
| FY 2027 | $-0.16 | $-0.16 | $-0.16 | 1 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Dec 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Mar 2027 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Jun 2027 | $0.00 | $0.00 | $0.00 | 0 |
Annual
| Period | Low |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $276.00M | $276.00M | $276.00M | 1 |
| FY 2027 | $40.00M | $40.00M | $40.00M | 1 |
